Group 1 - The Hong Kong innovative drug sector is experiencing a rebound, with the Hang Seng Innovative Drug Index rising by 4.0% as of 14:50, and notable increases in stocks such as Luye Pharma (over 8%) and CSPC Pharmaceutical Group (over 7%) [1] - China's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Analysts suggest that with the onset of a global interest rate cut cycle, there is significant potential for Chinese innovative drugs to capitalize on international opportunities, potentially leading to breakthroughs in the global innovative drug industry [1] Group 2 - The Hang Seng Innovative Drug Index has recently undergone adjustments to exclude contract research organizations (CROs), resulting in a "pure" index that more accurately reflects the performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index and has been attracting significant investment, aiding investors in strategically positioning themselves within the innovative drug sector [2]

Group 1 - The Hong Kong innovative drug sector has seen significant gains, with companies like Innovent Biologics and BeiGene rising over 5%, leading to a 3.12% increase in the Hang Seng Innovative Drug ETF (159316) [1] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which has received a net inflow of 828 million yuan over the past 20 days, bringing its total size to 1.715 billion yuan [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index underwent an adjustment on August 11, removing CXO companies to become a "pure" 100% innovative drug index, which is expected to better reflect the overall performance of Chinese innovative drug companies [1] Group 2 - The innovative drug sector in China is expected to have more growth potential following the onset of a global interest rate cut cycle, which could improve the investment environment significantly [2] - The essence of Chinese innovative drugs going global this year is to leverage national advantages to replace certain ecological niches of overseas biotech, indicating a strategic shift in the industry [2] - If a new round of interest rate cuts occurs overseas, the global innovative drug industry may experience breakthroughs, leading to a period of prosperity for both Chinese and American innovative drug sectors [2]